GLP-1 Price Guide Compare prices
Next-Gen GLP-1 · June 1, 2026

Retatrutide vs Tirzepatide: What Early Research Suggests

Phase 2 retatrutide data shows greater mean weight loss than Phase 3 tirzepatide data. Phase 3 retatrutide results are pending.

Retatrutide & Next-GenJune 1, 2026Editorial

Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026

Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework
FactorTirzepatide (Zepbound)Retatrutide (investigational)
ReceptorsGLP-1 + GIP (dual)GLP-1 + GIP + glucagon (triple)
PhaseMarketed (FDA-approved)Phase 3 (TRIUMPH program)
Mean weight loss (high dose)~22% at 72 weeks (SURMOUNT-1)~24% at 48 weeks (Phase 2)
Commercial availabilityYes (FDA-approved Zepbound)No (clinical trials only)

Phase 3 retatrutide data is not yet published. If Phase 3 readouts support Phase 2 efficacy and safety, FDA submission is projected 2026-2027 with potential approval 2027-2028.

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.

Frequently asked questions

Is retatrutide FDA-approved?
No. Retatrutide is investigational and is not FDA-approved for weight loss. The FDA has warned about unapproved products containing retatrutide falsely marketed online.
Can I buy retatrutide online?
Retatrutide is not commercially available as an approved medication. Avoid websites selling “research” retatrutide for human use — these are not legitimate pharmacy products.
How does retatrutide differ from tirzepatide?
Retatrutide is an investigational triple-agonist studied in the TRIUMPH trials; tirzepatide is a dual agonist. Early research is promising, but retatrutide remains investigational and should not be framed as commercially available.
What GLP-1 options are available now?
Approved and compounded semaglutide and tirzepatide programs are available through licensed telehealth providers. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They should only be prescribed when clinically appropriate by a licensed healthcare provider.

Related pricing tools & guides